Increased serum interleukin-6 levels in early stages of psychosis: Associations with at-risk mental states and the severity of psychotic symptoms

Psychoneuroendocrinology

Volumn 41, Issue , 2014, Pages 23-32

  Stojanovic, Alexander ^a   Martorell, Lourdes ^a   Montalvo, Itziar ^a   Ortega, Laura ^a   Monseny, Rosa ^a   Vilella, Elisabet ^a   Labad, Javier ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

At risk mental state (ARMS); C reactive protein (CRP); Early psychosis; IL 6; Inflammation; Rs1800795; Schizophrenia

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; GENOMIC DNA; INTERLEUKIN 6; BIOLOGICAL MARKER;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA EXTRACTION; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; GENDER; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOM; TOBACCO CONSUMPTION; ADOLESCENT; BLOOD; CASE CONTROL STUDY; COMPLICATION; EARLY DIAGNOSIS; GENETICS; MENTAL DISEASE; METABOLISM; MICROBIOLOGY; PRODROMAL SYMPTOM; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; EARLY DIAGNOSIS; FEMALE; FIBRINOGEN; HUMANS; INTERLEUKIN-6; MALE; MENTAL DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRODROMAL SYMPTOMS; PSYCHOTIC DISORDERS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84893393902     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2013.12.005     Document Type: Article

References (53)

1. Altamura A.C., Boin F., Maes M. HPA axis and cytokines dysregulation in schizophrenia: potential implications for the antipsychotic treatment. Eur. Neuropsychopharmacol. 1999, 10:1-4.
2. Aranda N., Viteri F.E., Fernandez-Ballart J., Murphy M., Arija V. Frequency of the hemochromatosis gene (HFE) 282C-->Y, 63H-->D, and 65S-->C mutations in a general Mediterranean population from Tarragona, Spain. Ann. Hematol. 2007, 86:17-21.
3. Borovcanin M., Jovanovic I., Radosavljevic G., Djukic Dejanovic S., Bankovic D., Arsenijevic N., Lukic M.L. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. J. Psychiatr. Res. 2012, 46:1421-1426.
4. Cardellini M., Perego L., D'Adamo M., Marini M.A., Procopio C., Hribal M.L., Andreozzi F., Frontoni S., Giacomelli M., Paganelli M., Pontiroli A.E., Lauro R., Folli F., Sesti G. C-174G polymorphism in the promoter of the interleukin-6 gene is associated with insulin resistance. Diabetes Care 2005, 28:2007-2012.
5. Dickerson F., Stallings C., Origoni A., Boronow J., Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr. Res. 2007, 93:261-265.
6. Fan X., Pristach C., Liu E.Y., Freudenreich O., Henderson D.C., Goff D.C. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res. 2007, 149:267-271.
7. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 1998, 102:1369-1376.
8. Fusar-Poli P., Borgwardt S., Bechdolf A., Addington J., Riecher-Rossler A., Schultze-Lutter F., Keshavan M., Wood S., Ruhrmann S., Seidman L.J., Valmaggia L., Cannon T., Velthorst E., De Haan L., Cornblatt B., Bonoldi I., Birchwood M., McGlashan T., Carpenter W., McGorry P., Klosterkotter J., McGuire P., Yung A. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 2013, 70:107-120.
9. Ganguli R., Yang Z., Shurin G., Chengappa K.N., Brar J.S., Gubbi A.V., Rabin B.S. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res. 1994, 51:1-10.
10. Garcia-Rizo C., Fernandez-Egea E., Oliveira C., Justicia A., Bernardo M., Kirkpatrick B. Inflammatory markers in antipsychotic-naive patients with nonaffective psychosis and deficit vs. nondeficit features. Psychiatry Res. 2012, 198:212-215.
11. Gardner D.M., Murphy A.L., O'Donnell H., Centorrino F., Baldessarini R.J. International consensus study of antipsychotic dosing. Am. J. Psychiatry 2010, 167:686-693.
12. Isshiki H., Akira S., Tanabe O., Nakajima T., Shimamoto T., Hirano T., Kishimoto T. Constitutive and interleukin-1 (IL-1)-inducible factors interact with the IL-1-responsive element in the IL-6 gene. Mol. Cell. Biol. 1990, 10:2757-2764.
13. Kaplan B.L. The role of CB1 in immune modulation by cannabinoids. Pharmacol. Ther. 2013, 137:365-374.
14. Kim Y.K., Kim L., Lee M.S. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr. Res. 2000, 44:165-175.
15. Kishimoto T. IL-6: from its discovery to clinical applications. Int. Immunol. 2010, 22:347-352.
16. Levy J.H., Szlam F., Tanaka K.A., Sniecienski R.M. Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. Anesth. Analg. 2012, 114:261-274.
17. Lin A., Kenis G., Bignotti S., Tura G.J., De Jong R., Bosmans E., Pioli R., Altamura C., Scharpe S., Maes M. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res. 1998, 32:9-15.
18. Lobo A., Perez-Echeverria M.J., Artal J. Validity of the scaled version of the General Health Questionnaire (GHQ-28) in a Spanish population. Psychol. Med. 1986, 16:135-140.
19. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 1995, 29:141-152.
20. Maes M., Delange J., Ranjan R., Meltzer H.Y., Desnyder R., Cooremans W., Scharpe S. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res. 1997, 66:1-11.
21. Martorell L., Costas J., Valero J., Gutierrez-Zotes A., Phillips C., Torres M., Brunet A., Garrido G., Carracedo A., Guillamat R., Valles V., Guitart M., Labad A., Vilella E. Analyses of variants located in estrogen metabolism genes (ESR1, ESR2, COMT and APOE) and schizophrenia. Schizophr. Res. 2008, 100:308-315.
22. Miller B.J., Buckley P.F. Is relapse in schizophrenia an immune-mediated effect?. FOCUS: J. Lifelong Learn. Psychiatry 2012, 10:115-123.
23. Miller B.J., Culpepper N., Rapaport M.H. C-reactive protein levels in schizophrenia. Clin. Schizophr. Relat. Psychoses 2013, 1-22.
24. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70:663-671.
25. Morera A.L., Henry M., Garcia-Hernandez A., Fernandez-Lopez L. Acute phase proteins as biological markers of negative psychopathology in paranoid schizophrenia. Actas Esp. Psiquiatr. 2007, 35:249-252.
26. Muller N., Empl M., Riedel M., Schwarz M., Ackenheil M. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 1997, 247:308-313.
27. Muller N., Riedel M., Gruber R., Ackenheil M., Schwarz M.J. The immune system and schizophrenia. An integrative view. Ann. N. Y. Acad. Sci. 2000, 917:456-467.
28. Pandey R., Mousawy K., Nagarkatti M., Nagarkatti P. Endocannabinoids and immune regulation. Pharmacol. Res. 2009, 60:85-92.
29. Paul-Samojedny M., Owczarek A., Kowalczyk M., Suchanek R., Palacz M., Kucia K., Fila-Danilow A., Borkowska P., Kowalski J. Association of interleukin 2 (IL-2), interleukin 6 (IL-6), and TNF-alpha (TNFalpha) gene polymorphisms with paranoid schizophrenia in a Polish population. J. Neuropsychiatry Clin. Neurosci. 2013, 25:72-82.
30. Peralta V., Cuesta M.J. Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. Psychiatry Res. 1994, 53:31-40.
31. Pfafflin A., Schleicher E. Inflammation markers in point-of-care testing (POCT). Anal. Bioanal. Chem. 2009, 393:1473-1480.
32. Pollmacher T., Hinze-Selch D., Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J. Clin. Psychopharmacol. 1996, 16:403-409.
33. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 2008, 63:801-808.
34. Pruessner M., Iyer S.N., Faridi K., Joober R., Malla A.K. Stress and protective factors in individuals at ultra-high risk for psychosis, first episode psychosis and healthy controls. Schizophr. Res. 2011, 129:29-35.
35. Rodriguez S., Gaunt T.R., Day I.N. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am. J. Epidemiol. 2009, 169:505-514.
36. Roig B., Virgos C., Franco N., Martorell L., Valero J., Costas J., Carracedo A., Labad A., Vilella E. The discoidin domain receptor 1 as a novel susceptibility gene for schizophrenia. Mol. Psychiatry 2007, 12:833-841.
37. Rothermundt M., Missler U., Arolt V., Peters M., Leadbeater J., Wiesmann M., Rudolf S., Wandinger K.P., Kirchner H. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol. Psychiatry 2001, 6:445-449.
38. Saito V.M., Rezende R.M., Teixeira A.L. Cannabinoid modulation of neuroinflammatory disorders. Curr. Neuropharmacol. 2012, 10:159-166.
39. Saus E., Soria V., Escaramis G., Crespo J.M., Valero J., Gutierrez-Zotes A., Martorell L., Vilella E., Menchon J.M., Estivill X., Gratacos M., Urretavizcaya M. A haplotype of glycogen synthase kinase 3beta is associated with early onset of unipolar major depression. Genes Brain Behav. 2010, 9:799-807.
40. Schwarz M.J., Riedel M., Ackenheil M., Muller N. Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol. Psychiatry 2000, 47:29-33.
41. Shi J., Gershon E.S., Liu C. Genetic associations with schizophrenia: meta-analyses of 12 candidate genes. Schizophr. Res. 2008, 104:96-107.
42. Shrivastava A., McGorry P.D., Tsuang M., Woods S.W., Cornblatt B.A., Corcoran C., Carpenter W. Attenuated psychotic symptoms syndrome as a risk syndrome of psychosis, diagnosis in DSM-V: the debate. Indian J. Psychiatry 2011, 53:57-65.
43. Smith R.S. A comprehensive macrophage-T-lymphocyte theory of schizophrenia. Med. Hypotheses 1992, 39:248-257.
44. Soria V., Martinez-Amoros E., Escaramis G., Valero J., Perez-Egea R., Garcia C., Gutierrez-Zotes A., Puigdemont D., Bayes M., Crespo J.M., Martorell L., Vilella E., Labad A., Vallejo J., Perez V., Menchon J.M., Estivill X., Gratacos M., Urretavizcaya M. Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder. Neuropsychopharmacology 2010, 35:1279-1289.
45. Udina M., Moreno-Espana J., Navines R., Gimenez D., Langohr K., Gratacos M., Capuron L., de la Torre R., Sola R., Martin-Santos R. Serotonin and interleukin-6: the role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms. Psychoneuroendocrinology 2013, 38:1803-1813.
46. van Os J., Kenis G., Rutten B.P. The environment and schizophrenia. Nature 2010, 468:203-212.
47. Vazquez-Barquero J.L., Gaite L., Artal Simon J., Arenal A., Herrera Castanedo S., Diez Manrique J.F., Cuesta Nunez M.J., Higuera A. Development and verification of the Spanish version of the "scanning system" psychiatric interview ("Questionnaires for clinical evaluation in neuropsychiatry"). Actas Luso Esp. Neurol. Psiquiatr. Cienc. Afines 1994, 22:109-120.
48. Vilella E., Costas J., Sanjuan J., Guitart M., De Diego Y., Carracedo A., Martorell L., Valero J., Labad A., De Frutos R., Najera C., Molto M.D., Toirac I., Guillamat R., Brunet A., Valles V., Perez L., Leon M., de Fonseca F.R., Phillips C., Torres M. Association of schizophrenia with DTNBP1 but not with DAO, DAOA, NRG1 and RGS4 nor their genetic interaction. J. Psychiatr. Res. 2008, 42:278-288.
49. Vozarova B., Fernandez-Real J.M., Knowler W.C., Gallart L., Hanson R.L., Gruber J.D., Ricart W., Vendrell J., Richart C., Tataranni P.A., Wolford J.K. The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians. Hum. Genet. 2003, 112:409-413.
50. Xu M., He L. Convergent evidence shows a positive association of interleukin-1 gene complex locus with susceptibility to schizophrenia in the Caucasian population. Schizophr. Res. 2010, 120:131-142.
51. Yung A.R., Phillips L.J., Yuen H.P., Francey S.M., McFarlane C.A., Hallgren M., McGorry P.D. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr. Res. 2003, 60:21-32.
52. Yung A.R., Yuen H.P., McGorry P.D., Phillips L.J., Kelly D., Dell'Olio M., Francey S.M., Cosgrave E.M., Killackey E., Stanford C., Godfrey K., Buckby J. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust. N. Z. J. Psychiatry 2005, 39:964-971.
53. Zakharyan R., Petrek M., Arakelyan A., Mrazek F., Atshemyan S., Boyajyan A. Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia. Tissue Antigens 2012, 80:136-142.